Samjin Pharmaceutical Discloses Corporate Governance Report: Share Buyback of 580,000 Shares, Stable Dividend Policy, and Ongoing Governance Improvements
Samjin Pharmaceutical disclosed its 2025 corporate governance report, stating compliance with 7 out of 15 key governance indicators and strengthening independence by appointing all 3 outside directors as audit committee members.
On November 25, 2025, the company completed the cancellation of 580,000 common shares (approximately KRW 11.8 billion), a positive factor for shareholder value enhancement.
The dividend policy aims to distribute at least 20% of net income (standalone) over 2025-2027, maintaining a stable cash dividend of KRW 800 per share for the past 5 years. A charter amendment in 2026 improved dividend predictability.
[AI Summary]The report primarily confirms governance improvement efforts and shareholder return policies without fundamental positive or negative surprises. The share cancellation and stable dividend are positive for mid-to-long-term trust, but non-compliance items (e.g., no electronic voting) limit short-term stock price impact.